Headlines Covid-19 Specialties Trending Feeds Videos

Study Identifies Oncology Health Professionals’ Conflicting Perceptions of Telehealth

posted 3 hours


Cancer Network - The results of a study on telehealth give insight into both the potential barriers and possible benefits of these services, which have been widely...

Toni Choueiri, MD, on How New Data Impact the Standard of Care for RCC

posted 1 day


Cancer Network - An expert discusses how new data from the phase 3 CheckMate 9ER trial impact therapy choice in previously untreated advanced renal cell...

Cancer Network - Guidelines released by the Society for Immunotherapy of Cancer are intended to provide clinicians with the most current thinking on how experts can integrate...

Model Provides Template for High-Income & Emerging Economies to Plan Cancer Surgery Provision

posted 1 day


Cancer Network - Investigators suggested that a new model could be used to identify service gaps at the population level after adjusting to the important local variations...

Robert J. Motzer, MD, on Next Steps for the Phase 3 CLEAR Trial for Advanced RCC

posted 1 day


Cancer Network - Investigators compared lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma in the CLEAR...

Michael Szarek, PhD, on the Rationale Behind Conducting a Q-TWiST Analysis of the Phase 3 TIVO-3 Study

posted 1 day


Cancer Network - A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3...

Adjuvant Pazopanib Does Not Improve Overall Survival for Patients With Locally Advanced RCC

posted 1 day


Cancer Network - Follow-up data published in the European Association of Urology did not find a significant improvement in overall survival for patients with locally advanced renal...

Adjuvant Osimertinib Does Not Adversely Affect Health-Related QOL for EGFR+ NSCLC

posted 1 day


Cancer Network - Patients with EGFR-positive non–small cell lung cancer who received treatment with osimertinib following surgery versus placebo experienced no clinically meaningful differences in health-related quality...

AstraZeneca Withdraws Durvalumab Indication for Previously Treated Locally Advanced or Metastatic Bladder Cancer

posted 12 hours


Cancer Network - Continued approval for durvalumab in previously treated adult patients with locally advanced or metastatic bladder cancer was dependent upon results from the phase 3...

FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Cancer

posted 10 hours


Cancer Network - Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian...